Doravirine is a non-nucleoside reverse transcriptase inhibitor, a newer member of a class whose older drugs were effective but frequently difficult. It was designed to keep the effectiveness and lose the problems.
What kind of drug is it?
A non-nucleoside, which works differently from the nucleoside analogues despite targeting the same enzyme. Where nucleosides pose as building blocks, non-nucleosides disable the enzyme directly.
How does it work?
HIV must convert its RNA genome into DNA using reverse transcriptase. Doravirine binds to a pocket on the enzyme itself, changing its shape so that it can no longer perform that conversion properly.
Why does the difference matter?
Because it means non-nucleosides act at the same step by a separate route, so they combine well with nucleoside analogues. It also means their resistance pathways differ, which affects what remains usable if a regimen fails.
What was it designed to improve on?
Efavirenz, mainly, which dominated HIV treatment for years despite causing vivid dreams, dizziness, mood changes and raised cholesterol. Doravirine was developed to retain the class's effectiveness without those effects.
Does it work against resistant virus?
Against some. It retains activity against several common mutations that defeat efavirenz and nevirapine, which was a deliberate design goal. It is not active against every non-nucleoside resistance pattern, and testing determines whether it is appropriate.
What is it used for?
HIV treatment as part of a combination, both for people starting treatment and for people switching from another regimen while suppressed.
Does it need a booster?
No. It maintains useful levels for a full day on its own, which avoids the interaction problems that ritonavir and cobicistat create.
Does it have a food requirement?
No, which distinguishes it from rilpivirine, the other modern non-nucleoside. That makes it considerably easier to take for anyone whose eating pattern is irregular.
What is its resistance barrier?
Better than older non-nucleosides and lower than dolutegravir, bictegravir or boosted darunavir. The class as a whole is more vulnerable to resistance developing where doses are missed, which matters when choosing for someone whose adherence is likely to be irregular.
How quickly does it work?
Quickly. Non-nucleosides reduce viral load rapidly, comparably to integrase inhibitors in the early phase, with suppression usually established within one to six months.
Does it cover hepatitis B?
Doravirine itself does not. The combination tablet containing it also contains lamivudine and tenofovir disoproxil, both of which do, which makes that product suitable where both infections are present.
What is its main advantage?
A favourable lipid profile. In comparative studies cholesterol and triglycerides were lower than on efavirenz or boosted darunavir, which matters for anyone with cardiovascular risk factors.
Where does it sit in current practice?
A reasonable alternative rather than a first choice for most people, since integrase inhibitors are preferred on resistance barrier. It is useful where an integrase inhibitor is unsuitable or has caused problems.
Where does it sit against the alternatives?
No antiretroviral is best in every situation. The fit depends on your lipids, your resistance history, what you have tolerated before and what else you take.
What happens when you start it?
Baseline blood tests first, covering kidney and liver function, lipids, viral load and CD4 count, plus hepatitis status and a resistance test. A follow-up appointment usually comes a few weeks later to check tolerability and early response.
Will you have to take it forever?
HIV treatment continues indefinitely, and what you take changes over the years. Being on doravirine now does not commit you to it permanently, and most people are on something different a decade later as options improve.
Does it stop you passing HIV on?
Any regimen that achieves and sustains an undetectable viral load does, including this one. Once suppression is sustained, HIV is not transmitted sexually. That is a property of effective treatment rather than of doravirine specifically.
What should you ask when it is first offered?
What this regimen requires daily, which side effects are common in the first month, what to do about a missed dose, and what the alternatives would be if it does not suit. Those four questions at the outset save a good deal later.